BACKGROUND: Inhaled nitric oxide (iNO) is an effective therapy for pulmonary hypertension and hypoxic respiratory failure in term infants. Fourteen randomized controlled trials (n = 3430 infants) have been conducted on preterm infants at risk for chronic lung disease (CLD). The study results seem contradictory. DESIGN/ METHODS: Individual-patient data meta-analysis included randomized controlled trials of preterm infants (<37 weeks' gestation). Outcomes were adjusted for trial differences and correlation between siblings. RESULTS: Data from 3298 infants in 12 trials (96%) were analyzed. There was no statistically significant effect of iNO on death or CLD (59% vs 61%: relative risk [RR]: 0.96 [95% confidence interval (CI): 0.92-1.01]; P = .11) or severe neurologic events on imaging (25% vs 23%: RR: 1.12 [95% CI: 0.98-1.28]; P = .09). There were no statistically significant differences in iNO effect according to any of the patient-level characteristics tested. In trials that used a starting iNO dose of >5 vs ≤ 5 ppm there was evidence of improved outcome (interaction P = .02); however, these differences were not observed at other levels of exposure to iNO. This result was driven primarily by 1 trial, which also differed according to overall dose, duration, timing, and indication for treatment; a significant reduction in death or CLD (RR: 0.85 [95% CI: 0.74-0.98]) was found. CONCLUSIONS: Routine use of iNO for treatment of respiratory failure in preterm infants cannot be recommended. The use of a higher starting dose might be associated with improved outcome, but because there were differences in the designs of these trials, it requires further examination.
BACKGROUND: Inhaled nitric oxide (iNO) is an effective therapy for pulmonary hypertension and hypoxic respiratory failure in term infants. Fourteen randomized controlled trials (n = 3430 infants) have been conducted on preterm infants at risk for chronic lung disease (CLD). The study results seem contradictory. DESIGN/ METHODS: Individual-patient data meta-analysis included randomized controlled trials of preterm infants (<37 weeks' gestation). Outcomes were adjusted for trial differences and correlation between siblings. RESULTS: Data from 3298 infants in 12 trials (96%) were analyzed. There was no statistically significant effect of iNO on death or CLD (59% vs 61%: relative risk [RR]: 0.96 [95% confidence interval (CI): 0.92-1.01]; P = .11) or severe neurologic events on imaging (25% vs 23%: RR: 1.12 [95% CI: 0.98-1.28]; P = .09). There were no statistically significant differences in iNO effect according to any of the patient-level characteristics tested. In trials that used a starting iNO dose of >5 vs ≤ 5 ppm there was evidence of improved outcome (interaction P = .02); however, these differences were not observed at other levels of exposure to iNO. This result was driven primarily by 1 trial, which also differed according to overall dose, duration, timing, and indication for treatment; a significant reduction in death or CLD (RR: 0.85 [95% CI: 0.74-0.98]) was found. CONCLUSIONS: Routine use of iNO for treatment of respiratory failure in preterm infants cannot be recommended. The use of a higher starting dose might be associated with improved outcome, but because there were differences in the designs of these trials, it requires further examination.
Authors: William M Maniscalco; Richard H Watkins; Gloria S Pryhuber; Abhay Bhatt; Colleen Shea; Heidie Huyck Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-04 Impact factor: 5.464
Authors: Barbara Schmidt; Elizabeth V Asztalos; Robin S Roberts; Charlene M T Robertson; Reginald S Sauve; Michael F Whitfield Journal: JAMA Date: 2003-03-05 Impact factor: 56.272
Authors: Philip W Shaul; Sam Afshar; Linda L Gibson; Todd S Sherman; Jay D Kerecman; Peter H Grubb; Bradley A Yoder; Donald C McCurnin Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-07-07 Impact factor: 5.464
Authors: F Sessions Cole; Claudia Alleyne; John D E Barks; Robert J Boyle; John L Carroll; Deborah Dokken; William H Edwards; Michael Georgieff; Katherine Gregory; Michael V Johnston; Michael Kramer; Christine Mitchell; Josef Neu; DeWayne M Pursley; Walter M Robinson; David H Rowitch Journal: Pediatrics Date: 2011-01-10 Impact factor: 7.124
Authors: Jen-Ruey Tang; Neil E Markham; Yuh-Jyh Lin; Ivan F McMurtry; Anne Maxey; John P Kinsella; Steven H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2004-04-02 Impact factor: 5.464
Authors: Michael D Schreiber; Karen Gin-Mestan; Jeremy D Marks; Dezheng Huo; Grace Lee; Pimol Srisuparp Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow Journal: Pediatr Pulmonol Date: 2012-07-06
Authors: John P Kinsella; Gary R Cutter; Robin H Steinhorn; Leif D Nelin; William F Walsh; Neil N Finer; Steven H Abman Journal: J Pediatr Date: 2014-07-22 Impact factor: 4.406
Authors: Q Jiang; X Gao; C Liu; D Chen; X Lin; S Xia; D Zhuang; C Yang; W Zhu; L Liu; C Chen; B Sun Journal: J Perinatol Date: 2016-07-21 Impact factor: 2.521